Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients
New analysis from pivotal Phase III studies show Xolair (omalizumab) improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo.
Additional data at WCD show the consistent negative health impact and economic burden of CSU, including anxiety, depression, impact on work ability and health system costs.
CSU
CSU is a severe skin condition with symptoms such as persistent itching, swelling and a rash that spontaneously presents and re-occurs for more than six weeks.